Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Operating Leases (2019 - 2025)

Historic Operating Leases for China Pharma Holdings (CPHI) over the last 7 years, with Q3 2025 value amounting to $198583.0.

  • China Pharma Holdings' Operating Leases changed N/A to $198583.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $198583.0, marking a year-over-year change of. This contributed to the annual value of $39323.0 for FY2024, which is 147.08% down from last year.
  • Latest data reveals that China Pharma Holdings reported Operating Leases of $198583.0 as of Q3 2025.
  • Over the past 5 years, China Pharma Holdings' Operating Leases peaked at $198583.0 during Q3 2025, and registered a low of $20008.0 during Q1 2024.
  • Over the past 5 years, China Pharma Holdings' median Operating Leases value was $82959.0 (recorded in 2022), while the average stood at $88448.6.
  • Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 30754.59% in 2022, then crashed by 8108.36% in 2023.
  • Over the past 5 years, China Pharma Holdings' Operating Leases (Quarter) stood at $85282.0 in 2021, then tumbled by 52.57% to $40445.0 in 2022, then decreased by 1.32% to $39910.0 in 2023, then decreased by 1.47% to $39323.0 in 2024, then skyrocketed by 405.0% to $198583.0 in 2025.
  • Its last three reported values are $198583.0 in Q3 2025, $39323.0 for Q4 2024, and $20008.0 during Q1 2024.